Clin J Am Soc Nephro:肾病患者生存率得以提高!

2017-12-15 枫丹白露 来宝网

肾功能衰竭患者的死亡风险高于普通人群,但新的分析表明,这种风险正在下降。研究结果来自于即将出版的“美国肾脏病学会临床杂志”(CJASN)上发表的一项研究,令人鼓舞,并表明改善护理的努力已经改善了生存。

肾功能衰竭患者的生存率正在改善】肾功能衰竭患者的死亡风险高于普通人群,但新的分析表明,这种风险正在下降。研究结果来自于即将出版的“美国肾脏病学会临床杂志”(CJASN)上发表的一项研究,令人鼓舞,并表明改善护理的努力已经改善了生存。

虽然肾功能衰竭患者的早期死亡率随着时间的推移而下降,但是改善仅仅反映了一般人群的平行改善是未知的。为了进行调查,由Bethany Foster博士,MSCE(蒙特利尔儿童医院和麦吉尔大学健康中心研究所)和Benjamin Laskin博士(费城儿童医院)领导的一个小组研究了在美国被治疗肾衰竭的人群中早期过度风险的变化死亡超过一般人群的风险 。

这项分析包括1995年至2013年诊断为肾衰的1938148名儿童和成年人。1995年至2013年期间肾功能衰竭相关死亡风险过高的5年间变化因年龄而异,0-14岁从65%到27%。随着时间的推移,过量死亡率的降低在所有年龄段和透析治疗期间以及在肾功能正常的情况下都出现了,对于年龄最小的肾移植患者,观察到最大的相对改善。对于最老的患者来说,与肾衰竭相关的死亡率绝对值下降最大。

“我们发现,在过去的22年中,所有年龄组的死亡率风险都有了显着的提高,其中一些改进是由于肾移植的获得和肾移植的存活时间延长,但对透析治疗和肾移植患者的护理也有一些改善,“福斯特博士说。 “考虑到这些病人的资源投入巨大,这一点很重要,我们已经表明这些投资已经有所改变。”

福斯特博士指出,研究人员预计除了青春期晚期和成年早期以外,所有年龄组的死亡率都会下降。这个年龄组往往难以坚持推荐的治疗方法,而且当年轻人从儿科医疗机构转移到成人护理机构时,护理的连续性有时会中断。福斯特博士说:“我们发现,这个年龄段的年轻人在1995年至2006年期间的死亡率风险没有任何改善,与其他年龄组不同,但在2006年之后开始显着改善。 “这可能是因为医护人员在二十一世纪初更加关注这些问题,改变了他们照顾这些年轻人的方式。”

尽管肾功能衰竭患者的死亡风险仍然高于普通人群,但差距似乎逐渐缩小。福斯特博士说:“改善肾功能衰竭患者的健康状况的最好方法之一就是让他们进行肾移植,合适器官供应的有限仍然是肾功能衰竭患者获得更大进展的主要障碍。 “每个人都需要考虑捐献器官,签署器官捐赠卡。”

医学博士Kirsten Johansen博士(加利福尼亚大学旧金山分校)指出,该研究为将来的研究提供了一个框架,用于研究实践模式和临床护理中的哪些变化可能有助于改善患者终末期肾病的死亡率。她写道:“分析随着时间和地理区域的不同结果的差异,是我们可以运用的强大工具,以了解实践中的变化或变化对生存的影响。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932605, encodeId=c5d819326051b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Apr 03 12:18:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025832, encodeId=0bc720258322e, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Mar 24 01:18:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274497, encodeId=2b282e4497fd, content=好好好不好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon Jan 01 14:40:35 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273295, encodeId=e1362e329548, content= 好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:50 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273294, encodeId=90fb2e3294b5, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:20 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256617, encodeId=e9b5125661e6f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Dec 17 06:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269648, encodeId=3b36269648cd, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Dec 15 17:25:45 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932605, encodeId=c5d819326051b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Apr 03 12:18:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025832, encodeId=0bc720258322e, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Mar 24 01:18:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274497, encodeId=2b282e4497fd, content=好好好不好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon Jan 01 14:40:35 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273295, encodeId=e1362e329548, content= 好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:50 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273294, encodeId=90fb2e3294b5, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:20 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256617, encodeId=e9b5125661e6f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Dec 17 06:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269648, encodeId=3b36269648cd, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Dec 15 17:25:45 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932605, encodeId=c5d819326051b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Apr 03 12:18:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025832, encodeId=0bc720258322e, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Mar 24 01:18:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274497, encodeId=2b282e4497fd, content=好好好不好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon Jan 01 14:40:35 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273295, encodeId=e1362e329548, content= 好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:50 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273294, encodeId=90fb2e3294b5, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:20 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256617, encodeId=e9b5125661e6f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Dec 17 06:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269648, encodeId=3b36269648cd, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Dec 15 17:25:45 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2018-01-01 zwjnj2

    好好好不好好学习天天向上

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1932605, encodeId=c5d819326051b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Apr 03 12:18:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025832, encodeId=0bc720258322e, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Mar 24 01:18:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274497, encodeId=2b282e4497fd, content=好好好不好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon Jan 01 14:40:35 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273295, encodeId=e1362e329548, content= 好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:50 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273294, encodeId=90fb2e3294b5, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:20 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256617, encodeId=e9b5125661e6f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Dec 17 06:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269648, encodeId=3b36269648cd, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Dec 15 17:25:45 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-28 Mengshentina

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1932605, encodeId=c5d819326051b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Apr 03 12:18:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025832, encodeId=0bc720258322e, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Mar 24 01:18:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274497, encodeId=2b282e4497fd, content=好好好不好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon Jan 01 14:40:35 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273295, encodeId=e1362e329548, content= 好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:50 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273294, encodeId=90fb2e3294b5, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:20 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256617, encodeId=e9b5125661e6f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Dec 17 06:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269648, encodeId=3b36269648cd, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Dec 15 17:25:45 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-28 Mengshentina

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1932605, encodeId=c5d819326051b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Apr 03 12:18:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025832, encodeId=0bc720258322e, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Mar 24 01:18:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274497, encodeId=2b282e4497fd, content=好好好不好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon Jan 01 14:40:35 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273295, encodeId=e1362e329548, content= 好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:50 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273294, encodeId=90fb2e3294b5, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:20 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256617, encodeId=e9b5125661e6f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Dec 17 06:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269648, encodeId=3b36269648cd, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Dec 15 17:25:45 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1932605, encodeId=c5d819326051b, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Apr 03 12:18:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2025832, encodeId=0bc720258322e, content=<a href='/topic/show?id=a91d82583bf' target=_blank style='color:#2F92EE;'>#肾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82583, encryptionId=a91d82583bf, topicName=肾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sat Mar 24 01:18:00 CST 2018, time=2018-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274497, encodeId=2b282e4497fd, content=好好好不好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Mon Jan 01 14:40:35 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273295, encodeId=e1362e329548, content= 好, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:50 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273294, encodeId=90fb2e3294b5, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/28/3dba1487ba62f9cd60d33531fe8fd593.jpg, createdBy=53342224215, createdName=Mengshentina, createdTime=Thu Dec 28 21:45:20 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256617, encodeId=e9b5125661e6f, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Sun Dec 17 06:18:00 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269648, encodeId=3b36269648cd, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Dec 15 17:25:45 CST 2017, time=2017-12-15, status=1, ipAttribution=)]
    2017-12-15 三生有幸9135

    学习一下谢谢分享

    0

相关资讯

Science:科学家发现新化合物可击败慢性肾病!

进行性肾脏疾病,无论是由肥胖,高血压,糖尿病还是罕见的基因突变引起的,往往都有相同的结果:负责过滤血液的细胞被破坏。麻省理工学院和哈佛大学,布里格姆妇女医院和哈佛医学院的研究人员领导的一个研究小组今天在“科学”杂志上报道了一个新的方法来预防这些重要的肾细胞死亡。研究多种肾病动物模型,研究小组发现了一种能够阻止滤过细胞丢失并恢复肾脏功能的化合物。这项研究的灵感来源于对遗传形式的调查,可能影响数百万患

JAMA:抗抑郁药物不适用于慢性肾病患者

已有的报导显示,重度抑郁症(MDD)在慢性肾病(CKD)患者中普遍存在,并且与患者发病率和死亡率相关。但是至今为止,选择性5-羟色胺再摄取抑制剂在这些患者中的功效和不良反应还是未知的。

诊间日记:老年人常患的肾病有哪些,老年人日常怎样养肾?

老年人常患的肾病有:一、糖尿病肾病和高血压性肾脏病高血压和糖尿病是目前最常见的慢性病。一般来说,二者中年以后发生,如果不加控制,持续5-10年就会出现肾损害,差不多这个时候已进入老年期,所以糖尿病肾病和高血压性肾脏病是老年人常见的肾病。在欧美国家,糖尿病和高血压是慢性肾脏病最常见的两大原因。一直以来,我国居民慢性肾脏病的常见原因是慢性肾小球肾炎,但自2016年开始,糖尿病已经超过慢性肾炎而成为我国

Kidney int:中美洲肾病(Mesoamerican nephropathy)知多少?

中美洲肾病(Mesoamerican nephropathy)是一种病因不明的破坏性疾病,主要影响中美洲年轻的农业工人。目前,迫切需要了解该疾病的损伤机制和早期疾病进展过程,这将有助于确定疾病的根本原因,并进行针对性的直接治疗和预防工作。近期,一篇发表在杂志Kidney int上的文章前瞻性地描述了尼加拉瓜地区,急性患者发生最早临床表现时的中美洲肾病肾脏病理。研究者们考虑将血清肌酐、白细胞尿和白细

J Intern Med:对于慢性肾病患者,严格控制血压可能使情况更糟糕!

据“内科学杂志”10月16日在线发表的一项研究显示,控制血压(BP)可能对中度至进展期慢性肾病患者无益,甚至可能有害。

Kidney Int:肾病增加糖尿病风险

已知糖尿病会增加患者肾脏疾病的风险。现在,来自圣路易斯华盛顿大学医学院的一项新研究表明,反过来也是正确的:肾功能障碍增加了糖尿病的风险。